España
India
Italia
대한민êµ
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Inhibrx Biosciences
INBX
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$14.29
0.67
4.92%
At close: -
$13.62
-0.67
-4.69%
After Hours: Nov 18, 7:54 PM EDT
Get Report
Comment
Q3 2024 Earnings were released on Thu Nov 14th, after the market close
Inhibrx Biosciences (INBX) Forecast
News
Earnings
Inhibrx Biosciences (INBX) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Inhibrx Biosciences (NASDAQ:INBX) Stock
Inhibrx Biosciences Stock (NASDAQ: INBX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, November 14, 2024
Inhibrx Biosciences Q3 EPS $(2.84) Beats $(3....
Benzinga Newsdesk
Monday, November 04, 2024
Inhibrx Announces The Jury Found In Favor Of ...
Benzinga Newsdesk
Tuesday, September 03, 2024
Around $2M Bet On Franklin Resources? Check Out These 4 Stocks Executives Are Buying
Avi Kapoor
Tuesday, August 27, 2024
Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying
Avi Kapoor
Wednesday, August 14, 2024
Inhibrx Biosciences Q2 EPS $125.48, Sales $10...
Benzinga Newsdesk
Tuesday, July 23, 2024
JMP Securities Initiates Coverage On Inhibrx ...
Benzinga Newsdesk
Friday, June 07, 2024
Inhibrx Biosciences 13G Filing Shows Viking G...
Benzinga Newsdesk
Wednesday, June 05, 2024
Top 4 Health Care Stocks That Are Preparing To Pump This Month
Avi Kapoor
Friday, May 31, 2024
Trading Halt: Halt status updated at 8:40:00 ...
Benzinga Newsdesk
Friday, May 24, 2024
Inhibrx Approve Sale Of INBRX-101 To Sanofi; ...
Benzinga Newsdesk
Wednesday, February 28, 2024
Inhibrx Q4 2023 GAAP EPS $(1.73) Misses $(1.0...
Benzinga Newsdesk
Tuesday, January 23, 2024
Inhibrx shares are trading higher after the c...
Benzinga Newsdesk
French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2B
Vandana Singh
Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project
Benzinga Neuro
JMP Securities Downgrades Inhibrx to Market P...
Benzinga Newsdesk
Inhibrx Sells INBRX-101 To Sanofi For Up To $...
Benzinga Newsdesk
Monday, November 20, 2023
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
Thursday, November 16, 2023
Watching Axos Financial; The Bear Cave Newsle...
Benzinga Newsdesk
Thursday, November 09, 2023
Inhibrx Q3 EPS $(1.10)
Benzinga Newsdesk
Thursday, November 02, 2023
Inhibrx Announces Preliminary Data From The P...
Benzinga Newsdesk
Tuesday, September 19, 2023
Inhibrx Announces Chiesi Farmaceutici S.p.A d...
Benzinga Newsdesk
Thursday, August 31, 2023
$1.5M Bet On Domo? Check Out These 3 Stocks Insiders Are Buying
Lisa Levin
Tuesday, August 29, 2023
Why NIO Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On Tuesday
Lisa Levin
Inhibrx Announces $200M Private Placement Financing; In The PIPE, Co Is Selling An Aggregate Of 3,621,314 Shares Of Its Common Stock At A Price Of $19.35 Per Share
Happy Mohamed
Wednesday, August 23, 2023
JMP Securities Maintains Outperform Rating for Inhibrx: Here's What You Need To Know
Benzinga Insights
JMP Securities Maintains Outperform on Inhibr...
Benzinga Newsdesk
Monday, August 07, 2023
Inhibrx Q2 EPS $(1.08) Down From $(0.97) YoY,...
Benzinga Newsdesk
Tuesday, May 30, 2023
Inhibrx Granted Fast Track Designation For IN...
Benzinga Newsdesk
Wednesday, May 10, 2023
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
Wednesday, April 26, 2023
Inhibrx Resumes Patient Enrollment In INBRX-109 Studies In Cancer Patients
Vandana Singh
Inhibrx Initiates A Registration-Enabling Trial Of INBRX-101 In AATD And Announces Lift Of Partial Clinical Hold On INBRX-109 DR5 Agonist Trials
Happy Mohamed
Wednesday, March 08, 2023
JMP Securities Maintains Market Outperform on...
Benzinga Newsdesk
Tuesday, March 07, 2023
Credit Suisse Reiterates Outperform on Inhibr...
Benzinga Newsdesk
Monday, March 06, 2023
Inhibrx Q4 EPS $(0.95) Misses $(0.79) Estimat...
Benzinga Newsdesk
Wednesday, January 04, 2023
NorthStar Medical Radioisotopes And Inhibrx E...
Benzinga Newsdesk
Friday, November 18, 2022
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
Lisa Levin
Wednesday, November 16, 2022
Inhibrx Posts Updated Efficacy, Safety Data From Expansion Cohorts Of Bone Cancer Candidate
Vandana Singh
Inhibrx Announces Updated Efficacy And Safety...
Benzinga Newsdesk
Tuesday, November 08, 2022
Credit Suisse Maintains Outperform on Inhibrx...
Benzinga Newsdesk
Monday, November 07, 2022
Inhibrx Q3 EPS $(0.90) Down From $(0.54) YoY,...
Benzinga Newsdesk
Thursday, October 13, 2022
$40 Million Bet On Inhibrx? 3 Stocks Insiders Are Buying
Lisa Levin
Wednesday, October 05, 2022
Evercore ISI Group Maintains Outperform on In...
Benzinga Newsdesk
Tuesday, October 04, 2022
S&P 500 Rises 100 Points; Nasdaq Up 3%
Lisa Levin
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
Nasdaq Surges 250 Points; Crude Oil Rises Sharply
Lisa Levin
US Stocks Open Higher As Dow Jumps 550 Points
Lisa Levin
Inhibrx's Experimental Drug For Inherited Disease Capable For Accelerated FDA Approval, Shares Surge
Vandana Singh
Inhibrx shares are trading higher after the c...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch